UNICREDIT BANK/CALL/VERTEX PHARMACEUTICALS/400/0.1/18.06.25

UNICREDIT BANK/CALL/VERTEX PHARMACEUTICALS/400/0.1/18.06.25 Share Price

DE000HC7U359

Real-time BOERSE MUENCHEN 14:40:08 27/06/2024 BST
10.45 ^EUR	+1.16%

Current month	+13.39%
1 month	+12.04%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart VERTEX PHARMACEUTICALS INCORPORATED

Chart UNICREDIT BANK/CALL/VERTEX PHARMACEUTICALS/400/0.1/18.06.25

Latest news about VERTEX PHARMACEUTICALS INCORPORATED

Redburn Atlantic Initiates Vertex Pharmaceuticals at Buy With $545 Price Target	10:28am	MT
Piper Sandler Adjusts Price Target on Vertex Pharmaceuticals to $500 From $456, Maintains Overweight Rating	06-25	MT
Wells Fargo Adjusts Price Target on Vertex Pharmaceuticals to $555 From $540	06-24	MT
Vertex Pharmaceuticals Discloses 'Positive' Data From Phase 1/2 Trial of VX-880 to Treat Type 1 Diabetes	06-21	MT

More news

Quotes 5-day view

Date	Price	Change
27/06/24	10.45	+1.16%
26/06/24	10.33	+0.98%
25/06/24	10.23	-2.20%
24/06/24	10.46	+3.56%
21/06/24	10.1	-1.08%

Real-time BOERSE MUENCHEN

Last update June 27, 2024 at 02:40 pm

More quotes

Static data

Product type	Warrants
Buy / Sell	CALL
Underlying	VERTEX PHARMACEUTICALS INCORPORATED
Issuer	UniCredit
WKN	HC7U35
ISIN	DE000HC7U359
Date issued	30/06/2023
Strike	400 $
Maturity	18/06/2025 (356 Days)
Parity	10 : 1
Emission price	5.61 €
Emission volume	N/A
Settlement	Por diferencias
Currency	EUR

Technical Indicators

Highest since issue	11.25 €
Lowest since issue	4.09 €
Delta	0.82x
Omega	3.500
Premium	7.68x
Gearing	4.26x
Moneyness	1.188
Difference Strike	-75.56 $
Difference Strike %	-18.89%
Spread	0.04 €
Spread %	0.38%
Theoretical value	10.56
Implied Volatility	29.66 %
Total Loss Probability	26.19 %
Intrinsic value	7.170
Present value	3.390
Break even	513.13 €
Theta	-0.06x
Vega	0.11x
Rho	0.25x

Company Profile

Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).

Sector

More about the company

Ratings for Vertex Pharmaceuticals Incorporated

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Consensus: Vertex Pharmaceuticals Incorporated

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

474 USD

Average target price

468.3 USD

Spread / Average Target

-1.21%

Consensus